Department of Health and Social Care written question – answered at on 22 October 2020.
To ask the Secretary of State for Health and Social Care, what steps his Department has taken to respond to concerns raised by the Competition and Markets Authority on the pricing of (a) hydrocortisone tablets and (b) liothyronine tablets since 2016.
Concerns about potential drug pricing abuses are a matter for the Competition and Markets Authority (CMA). The CMA has several ongoing investigations into excessive prices of generic medicines. Where it has concern about the price of a generic medicine, the Department asks the CMA to investigate that price.
Yes1 person thinks so
No23 people think not
Would you like to ask a question like this yourself? Use our Freedom of Information site.